ORPHA:279891
Chronic endophthalmitis
Publications
329
64.3th percentile
Trials
0
Interventional, condition-specific
Researchers
941
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017203
- UMLS:C0154774
Additional Mondo synonyms (1)
endophthalmitis, chronic
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
329 matched papers (159 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 33 for broader category endophthalmitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
329
329 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
329 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
159 in the last 10 years · high confidence · 64.3th percentile (publications denominator)
Phrase hits: 329 · MeSH hits: 0
Who's working on it?
941
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Das T4 papers · 2021
Smt. Kanuri Santhamma Center for Vitreoretinal Diseases, Kallam Anji Reddy Campus, LV Prasad Eye Institute, Hyderabad, India.
Papers in Europe PMC - 02Flynn HW Jr4 papers · 2021
Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.
Papers in Europe PMC - 03Joseph J4 papers · 2023
Jhaveri Microbiology Services, LV Prasad Eye Institute, Hyderabad, Telangana, India.
Papers in Europe PMC - 04Miller D4 papers · 2021
Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.
Papers in Europe PMC - 05Dave VP3 papers · 2021
Smt. Kanuri Santhamma Center for Vitreoretinal Diseases, Kallam Anji Reddy Campus, LV Prasad Eye Institute, Hyderabad, India.
Papers in Europe PMC - 06Li S3 papers · 2023
Department of Ophthalmology, The Jinan Second People's Hospital, Jinan, China.
Papers in Europe PMC - 07Wang J3 papers · 2025
Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Papers in Europe PMC - 08Yannuzzi NA3 papers · 2021
Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, USA.
Papers in Europe PMC - 09Agrawal D2 papers · 2025
Cornea and Anterior Segment, MGM Eye Institute, Raipur, Chhattisgarh, India.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 33 trials are registered for endophthalmitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
33 interventional trials matched endophthalmitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: endophthalmitis
33
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03244072·NOT YET RECRUITING·Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Conditions: Endophthalmitis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 64 · after dedupe 62 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 62 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (62)
- isrctn·ISRCTN56596656·Not yet recruiting·Combination antifungal therapy for candida bloodstream infections
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15871371·No longer recruiting·A study to assess the safety, biological activity, tolerability and processing by the body of RO7200394 in participants with macular edema secondary to central retinal vein occlusion
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12839469·No longer recruiting·A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (≥2) lines of therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- ctis·2026-526368-18-00·Authorised·A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-523994-41-00·Authorised·A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
skipped — LLM skipped (--skip-llm)
- ctis·2025-525042-22-00·Authorised·A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD
skipped — LLM skipped (--skip-llm)
- ctis·2026-526804-59-00·Authorised·Real-World Effectiveness of the Adjuvanted RSVPreF3 Vaccine in Adults ≥60 Years: A Pragmatic Randomized Trial (BronquiVal)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524842-89-00·Authorised·HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523293-17-00·Authorised·SUNCET: Low sodium oxybate Use for Nocturnal Cluster headache: safety, Efficacy and Tolerability of XYWAV - a Phase 2 Randomized, Double-Blind, Placebo-Controlled, bi-center Study
skipped — LLM skipped (--skip-llm)
- ctis·2026-525234-39-00·Authorised·A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
skipped — LLM skipped (--skip-llm)
- ctis·2026-526237-26-00·Authorised, ongoing·A Trial to Evaluate the Safety and Drug Levels of Single and Multiple Oral Doses of AT-587 in Healthy Adults
skipped — LLM skipped (--skip-llm)
- ctis·2025-522165-30-00·Authorised·An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
skipped — LLM skipped (--skip-llm)
- ctis·2026-525594-39-00·Authorised·Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults.
(FAST 7)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524374-42-00·Authorised·Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial
RSVaxID
skipped — LLM skipped (--skip-llm)
- ctis·2024-518016-39-00·Authorised, recruiting·A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
skipped — LLM skipped (--skip-llm)
- ctis·2026-525442-30-00·Authorised·The RELEASE Trial: Reconsidering Long-Term Aspirin in the Elderly in Secondary Prevention of Cardiovascular Disease
skipped — LLM skipped (--skip-llm)
- ctis·2024-520319-42-01·Authorised·A Randomized, Delayed-Treatment Controlled, Phase 2 Pilot Study of Manualized MDMA-Assisted Therapy for Young Adults with Chronic Treatment-Resistant Major Depressive Disorder
skipped — LLM skipped (--skip-llm)
- ctis·2026-526840-10-00·Authorised·Bioequivalence Study of Dapagliflozin 10 mg
skipped — LLM skipped (--skip-llm)
- ctis·2026-526334-67-00·Authorised, recruiting·C6501003 - A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess Relative Bioavailability of PF-08653945 When Administered Across Different Injection Sites in Adults With Overweight or Obesity
skipped — LLM skipped (--skip-llm)
- ctis·2025-524855-30-00·Authorised·A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
skipped — LLM skipped (--skip-llm)
- ctis·2025-524148-36-00·Authorised·Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA
skipped — LLM skipped (--skip-llm)
- ctis·2025-524019-35-00·Authorised, ongoing·Three-part PK and PD study of AXN-027
skipped — LLM skipped (--skip-llm)
- ctis·2025-524722-17-00·Authorised·Short and long-term Hemodynamic and Physiological Effects of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
skipped — LLM skipped (--skip-llm)
- ctis·2025-524795-35-00·Authorised·Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Chronic endophthalmitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Chronic endophthalmitis" OR "endophthalmitis, chronic"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chronic endophthalmitis" OR "endophthalmitis, chronic"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"endophthalmitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:43:59.194Z